37 related articles for article (PubMed ID: 36777977)
1. Evaluation of Target Attainment for Tobramycin in Children and Adults with Cystic Fibrosis.
Struiken STL; Lobée D; Tuinen ELV; Touw DJ; Vaart HV; Bourgonje AR; Rottier BL; Koppelman GH; Mian P
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731170
[No Abstract] [Full Text] [Related]
2. Evaluating the Impact of Education on Pharmacist Tobramycin Dose Recommendations for Cystic Fibrosis and a Review of Perceptions on Pharmacist-Led Charting.
Le T; Lord L; Pignataro S; Simioni D; Cheah R
J Pharm Pract; 2022 Dec; 35(6):903-910. PubMed ID: 34013814
[TBL] [Abstract][Full Text] [Related]
3. Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis.
Ochs MA; Dillman NO; Caverly LJ; Chaffee VD
Pediatr Pulmonol; 2021 Dec; 56(12):3634-3643. PubMed ID: 33983680
[TBL] [Abstract][Full Text] [Related]
4. Review of Tobramycin Dosing in Pediatric Patients With Cystic Fibrosis.
Imburgia TA; Seagren RM; Christensen H; Lasarev MR; Bogenschutz MC
J Pediatr Pharmacol Ther; 2023; 28(1):63-70. PubMed ID: 36777977
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis.
Praet A; Bourguignon L; Vetele F; Breant V; Genestet C; Dumitrescu O; Doleans-Jordheim A; Reix P; Goutelle S
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0073721. PubMed ID: 34280011
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
Staubes BA; Metzger NL; Walker SD; Peasah SK
Pharmacotherapy; 2016 Jun; 36(6):623-30. PubMed ID: 27138730
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis.
Vandenbussche HL; Homnick DN
J Pediatr Pharmacol Ther; 2012 Jan; 17(1):67-77. PubMed ID: 23118659
[TBL] [Abstract][Full Text] [Related]
8. A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation.
Downes KJ; Grim A; Shanley L; Rubenstein RC; Zuppa AF; Gastonguay MR
Antimicrob Agents Chemother; 2022 May; 66(5):e0237721. PubMed ID: 35481751
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
10. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children.
Goldstein SL; Dahale D; Kirkendall ES; Mottes T; Kaplan H; Muething S; Askenazi DJ; Henderson T; Dill L; Somers MJG; Kerr J; Gilarde J; Zaritsky J; Bica V; Brophy PD; Misurac J; Hackbarth R; Steinke J; Mooney J; Ogrin S; Chadha V; Warady B; Ogden R; Hoebing W; Symons J; Yonekawa K; Menon S; Abrams L; Sutherland S; Weng P; Zhang F; Walsh K
Kidney Int; 2020 Mar; 97(3):580-588. PubMed ID: 31980139
[TBL] [Abstract][Full Text] [Related]
11. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
Bland CM; Pai MP; Lodise TP
Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
[TBL] [Abstract][Full Text] [Related]
12. Safety of Extended Interval Tobramycin in Cystic Fibrosis Patients Less an 6 Years Old.
Arends A; Pettit R
J Pediatr Pharmacol Ther; 2018; 23(2):152-158. PubMed ID: 29720918
[TBL] [Abstract][Full Text] [Related]
13. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
Barras MA; Serisier D; Hennig S; Jess K; Norris RL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
[TBL] [Abstract][Full Text] [Related]
14. Infectious Diseases Pharmacotherapy for Children With Cystic Fibrosis.
Molloy L; Nichols K
J Pediatr Health Care; 2015; 29(6):565-78; quiz 579-80. PubMed ID: 26498903
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
